Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease

Update Il y a 4 ans
Reference: NCT01315795

Woman and Man

  • | Country :
  • Belgium
  • | organs :
  • -
  • | Specialty :
  • -

Extract

An open-label, Phase II clinical study to evaluate the efficacy and safety of lanreotide autogel 90mg every 4 weeks in the treatment of symptomatic polycystic liver disease, including a dose escalation at month 6 to lanreotide autogel 120mg for non responders.


Inclusion criteria

  • Polycystic Liver Disease

Links